Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* A clinical diagnosis of osteoarthritis of the hip or knee~* End-stage degenerative joint disease~* Eligibility for primary unilateral total or partial joint replacement surgery~* Pain level moderate to severe and at such a level as to require daily doses of an opioid analgesic medication~Exclusion Criteria:~* Has a life-long history of seizure disorder or epilepsy~* Had any of the following within the preceding 1 year: mild or moderate traumatic brain injury, stroke, transient ischemic attack, or brain neoplasm~* Had a severe traumatic brain injury within 15 years of screening (consisting of one or more of the following: brain contusion, intracranial hematoma, either unconsciousness or post traumatic amnesia lasting for more than 24 hours)~* Joint pain not associated with gout, fibromyalgia, rheumatoid arthritis, other autoimmune disease~* History of alcohol or drug abuse~* chronic hepatitis B and C or HIV, active hepatitis B and C within 3 months~* Severely impaired renal function or moderately to severely impaired hepatic function~* History of cancer within past 2 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): Tapentadol IR (CG5503) 50mg for 14 days
- 002 (Type: EXPERIMENTAL): Tapentadol IR (CG5503) 75mg for 14 days
- 003 (Type: ACTIVE_COMPARATOR): oxycodone IR 10mg for 14 days
- 004 (Type: PLACEBO_COMPARATOR): placebo 1 capsule for 14 days
- 005 (Type: EXPERIMENTAL): Tapentadol ER (CG5503) flexible dose tablets and capsules 2 x a day for 28 days (100-500mg/day)
- 006 (Type: ACTIVE_COMPARATOR): oxycodone CR flexible dose tablets and capsules 2 x a day for 28 days (20-60mg/day)
- 007 (Type: PLACEBO_COMPARATOR): placebo Tablets and capsules 2 x a day for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).